These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23818376)

  • 1. Tyrosine kinase inhibitors may change the metastatic pattern.
    Sendur MA; Aksoy S; Ozdemir NY; Zengin N
    J BUON; 2013; 18(2):544. PubMed ID: 23818376
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
    JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
    Hellmann MD; Reva B; Yu H; Rusch VW; Rizvi NA; Kris MG; Arcila ME
    J Thorac Oncol; 2014 Oct; 9(10):e73-4. PubMed ID: 25521405
    [No Abstract]   [Full Text] [Related]  

  • 4. Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
    Mathur G; Ma D
    J Thorac Oncol; 2014 Jul; 9(7):e55-e57. PubMed ID: 24926557
    [No Abstract]   [Full Text] [Related]  

  • 5. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
    Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
    Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
    de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
    J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
    [No Abstract]   [Full Text] [Related]  

  • 8. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
    Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
    Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
    Lim JU; Woo IS; Jung YH; Byeon JH; Park CK; Kim TJ; Kim HR
    Korean J Intern Med; 2014 Nov; 29(6):830-3. PubMed ID: 25378985
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
    Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
    Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
    Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
    [No Abstract]   [Full Text] [Related]  

  • 14. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
    Dillon B; Naidoo B; Knight H; Clark P
    Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted therapy: an evolving world of lung cancer.
    Lam KC; Mok TS
    Respirology; 2011 Jan; 16(1):13-21. PubMed ID: 20723139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
    Pongcharoen P; Chanprapaph K; Vachiramon V
    Arch Dermatol; 2011 Jun; 147(6):735-40. PubMed ID: 21690542
    [No Abstract]   [Full Text] [Related]  

  • 17. Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
    Funakoshi Y; Takeuchi Y; Maeda H
    Asian Cardiovasc Thorac Ann; 2013 Aug; 21(4):482-4. PubMed ID: 24570539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
    Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
    Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
    [No Abstract]   [Full Text] [Related]  

  • 19. Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib.
    Contreras-Díaz M; Medina-Tapia A; Martínez-Bernal G; Rueda-Rueda T; López-Herrero F; Molina-Socola FE; Sánchez-Vicente JL
    Arch Soc Esp Oftalmol; 2016 Nov; 91(11):551-555. PubMed ID: 27046001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.